Arrhythmia and Death Following Percutaneous Revascularization in Ischemic Left Ventricular Dysfunction: Prespecified Analyses From the REVIVED-BCIS2 Trial

Figures

• 

  Figure 1. CONSORT diagram. CAD indicates coronary artery disease; CONSORT, Consolidated Standards of Reporting Trials; CM, cardiomyopathy; LVSD, left ventricular systolic dysfunction; OMT, optimal medical therapy; and PCI, percutaneous coronary intervention. *Number screened and numbers excluded have been extrapolated from interval screening logs that were conducted during the trial at multiple centers.

• 

  Figure 2. Primary outcome of all-cause death or aborted sudden death over all follow-up. Kaplan-Meier estimates of the cumulative incidence of death from any cause or aborted sudden death in a time-to-first event analysis. Incidence includes total events over the entire follow-up period in each group in the intention-to-treat population, censored at death, withdrawal from the trial, or date of final follow-up encounter. HR indicates hazard ratio; OMT, optimal medical therapy; and PCI, percutaneous coronary intervention.

• 

  Figure 3. Primary outcome by prespecified subgroups. Forest plot showing hazard ratios for the primary outcome according to prespecified subgroups. Dashed line represents the null hypothesis of no treatment effect. The British Cardiovascular Intervention Society Jeopardy Score ranges from 0 to 12, with higher scores indicating a greater volume of myocardium subtended by diseased arteries. Implantable cardioverter defibrillator (ICD) indication (primary or secondary) includes both ICD and cardiac resynchronization therapy defibrillator implantations. Left ventricular ejection fraction (LVEF) change is from baseline to 6 months from core laboratory analyses; improved LVEF was defined as an improvement above the median change (>4.2%); unchanged or deteriorated LVEF was defined as below the median (≤4.2%). Recruiting center type defined by frequency of device implantation in the REVIVED-BCIS2 trial (Revascularisation for Ischaemic Ventricular Dysfunction): frequent if >50% of patients received a device, and infrequent if ≤50% received a device. NYHA indicates New York Heart Association heart failure class; OMT, optimal medical therapy; and PCI, percutaneous coronary intervention.

• 

  Figure 4. Cumulative device implantation by treatment group. The proportional hazards assumption seems to be violated (demonstrated by early separation of the curves, followed by gradual convergence over time); hence, a hazard ratio has not been calculated. OMT indicates optimal medical therapy; and PCI, percutaneous coronary intervention.